Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy

MT Newswires Live12-02

Cytokinetics (CYTK) said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic cardiomyopathy.

The decision was based on Cytokinetics' pivotal phase 3 clinical study for 24 weeks of aficamten that demonstrated that the inhibitor showed "significantly improved exercise capacity" compared with placebo, the company said.

The FDA has set Sept. 26, 2025, as the Prescription Drug User Fee Act date, the company said, adding that the FDA has not planned an advisory committee meeting to discuss the application.

Shares of the company were down more than 1% in recent Monday premarket activity.

Price: 51.00, Change: -0.86, Percent Change: -1.66

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488679279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488679279","market":"sg","top_or_hot":-1,"title":"Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> (CYTK) said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic cardiomyopathy.</p><p>The decision was based on Cytokinetics' pivotal phase 3 clinical study for 24 weeks of aficamten that demonstrated that the inhibitor showed \"significantly improved exercise capacity\" compared with placebo, the company said.</p><p>The FDA has set Sept. 26, 2025, as the Prescription Drug User Fee Act date, the company said, adding that the FDA has not planned an advisory committee meeting to discuss the application.</p><p>Shares of the company were down more than 1% in recent Monday premarket activity.</p><p>Price: 51.00, Change: -0.86, Percent Change: -1.66</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cytokinetics (CYTK) said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTK","symbol_name":"Cytokinetics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488679279","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488679279","pubTimestamp":1733146575,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cytokinetics  said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic cardiomyopathy.The decision was based on Cytokinetics' pivotal phase 3 clinical study for 24 weeks of aficamten that demonstrated that the inhibitor showed \"significantly improved exercise capacity\" compared with placebo, the company said.The FDA has set Sept. 26, 2025, as the Prescription Drug User Fee Act date, the company said, adding that the FDA has not planned an advisory committee meeting to discuss the application.Shares of the company were down more than 1% in recent Monday premarket activity.Price: 51.00, Change: -0.86, Percent Change: -1.66","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYTK":"Cytokinetics","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4588":"碎股"},"translate_title":"Cytokinetics称美国FDA接受Aficamten治疗梗阻性肥厚型心肌病新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1},"content_text":"Cytokinetics (CYTK) said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic cardiomyopathy.The decision was based on Cytokinetics' pivotal phase 3 clinical study for 24 weeks of aficamten that demonstrated that the inhibitor showed \"significantly improved exercise capacity\" compared with placebo, the company said.The FDA has set Sept. 26, 2025, as the Prescription Drug User Fee Act date, the company said, adding that the FDA has not planned an advisory committee meeting to discuss the application.Shares of the company were down more than 1% in recent Monday premarket activity.Price: 51.00, Change: -0.86, Percent Change: -1.66","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488679279"}